SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present a company overview at the virtual Sequire Biotechnology Conference on February 2, 2023, at 3:30 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present a company overview at the virtual Sequire Biotechnology Conference on February 2, 2023, at 3:30 p.m. Eastern Time. The conference will focus on SeaStar's innovative solutions aimed at mitigating hyperinflammation's effects on vital organs. Attendees can register for the event through the Sequire Biotechnology website. An archived webcast of the presentation will also be available on the SeaStar Medical website.
Details
News Market Reaction – ICU
The recorded move for ICU in the trading session of this news was -3.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 3:30 p.m. Eastern time.
To register for the event, visit the Sequire Biotechnology website. An achieved webcast of the presentation will be available on the SeaStar Medical website.
About Sequire
Sequire is a premier investor intelligence and communications platform where companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. More information is available at srax.com and mysequire.com.
About SeaStar Medical, Inc.
SeaStar Medical is a medical technology company focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or Twitter.
Contacts:
Media
PSC Consulting
Patty Caballero
(973) 348-5055
patty@pscconsulting.net
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.